Upadacitinib
Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen
Grundinformationen
- CAS
1310726-60-3- Standard-SMILES
CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12- InChIKey
WYQFJHHDOKWSHR-MNOVXSKESA-N- Summenformel
- C17H19F3N6O
- Durchschnittliche Molmasse
- 380,374 g/mol
- Monoisotopische Masse
- 380,15724389
Namen und Bezeichner
- Bevorzugter Name
- Upadacitinib
- Englischer Name
- Upadacitinib
- Summenformel
- C17H19F3N6O
- Molmasse
- 380.37
Namen und Synonyme
ABT-494(3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamideupatinibUpadacitinbUpadacitinib (ABT-494)ABT-494(Upadacitinib) free basebenzyl (4S)-3-(N-(ethoxycarbonyl)-N-(5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)glycyl)-4-ethylpyrrolidine-1-carboxylate1-Pyrrolidinecarboxamide, 3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-, (3S,4R)-(3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, UpadacitinibCS-2730
Datenbank-Bezeichner
- CAS
1310726-60-3- PubChem CID
- 58557659
- DTXSID
DTXSID901027919- ChEMBL
CHEMBL3622821- UNII
- 4RA0KN46E0
- Nikkaji
- J3.590.729G
Eigenschaften
Physikochemische Eigenschaften
- Dichte
- 1.56 · 1.56±0.1 g/cm3(Predicted)
- storage temp.
- -20 °C · Store at -20°C
- Löslichkeit
- 42.67 · DMSO:42.67(Max Conc. mg/mL);112.17(Max Conc. mM)DMSO:PBS (pH 7.2) (1:1):0.5(Max Conc. mg/mL);1.31(Max Conc. mM)DMF:30.0(Max Conc. mg/mL);78.87(Max Conc. mM)Ethanol:76.0(Max Conc. mg/mL);199.8(Max Conc. mM)
- Aggregatzustand
- A crystalline solid
- pka
- 11.89 · 11.89±0.60(Predicted)
- Farbe
- White to off-white
- InChI
- InChI=1S/C17H19F3N6O/c1-2-10-7-25(16(27)24-9-17(18,19)20)8-11(10)13-5-22-14-6-23-15-12(26(13)14)3-4-21-15/h3-6,10-11,21H,2,7-9H2,1H3,(H,24,27)/t10-,11+/m1/s1
- InChIKey
- WYQFJHHDOKWSHR-MNOVXSKESA-N
- SMILES
- N1(C(NCC(F)(F)F)=O)C[C@H](C2N3C4C=CNC=4N=CC3=NC=2)[C@H](CC)C1
Sicherheit und Regulatorisches
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Sicherheitsdaten
- Alarmwort
- Warnung
- Gefahrenhinweise
- Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code H302
Chemie und Industrie
Anwendungen
HistoryUpadacitinib was discovered by AbbVie scientists, RINVOQ is a JAK inhibitor that is being studied in several immune-mediated inflammatory diseases. In human leukocyte cellular assays, RINVOQ inhibited cytokine-induced STAT phosphorylation mediated by JAK1 and JAK1/JAK3 more potently than JAK2/JAK2 mediated STAT phosphorylation. Upadacitinib (RINVOQ) received FDA approval in 2019 for the treatment of moderate to severe RA.
VerwendenUpadacitinib also known as ABT-494, is a potent and selective Janus kinase (JAK) 1 inhibitor being developed for the treatment of several autoimmune disorders, Janus kinase inhibitors for rheumatoid arthritis. It is used to treat moderate to severely active rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis (a type of arthritis in the spine) with objective signs of swelling, moderate to severe ulcerative colitis, and moderate to severe Crohn's disease in patients who have taken other medicines (eg, methotrexate) that did not work well. It is also used to treat moderate to severe atopic dermatitis (eczema) in patients who have taken other medicines that did not work well and whose condition is not well controlled with other treatments or in patients who cannot tolerate these treatments. It is also used to treatpsoriatic arthritis, axial SpA and Giant Cell Arteritis and Takayasu Arteritis.
Vor- und nachgelagerte Produkte
Vorgelagerte Rohstoffe
Anbieter100 Anbieter
Zugehörige Reaktionen
0
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Notizen zur Verbindung
Wird geladen…